Work at Aligos Therapeutics Inc. has led to the discovery of new programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of hepatocellular carcinoma and hepatitis B.
Blossomhill Therapeutics Inc. have identified 7-azaindazole macrocycles acting as ALK tyrosine kinase receptor (mutant) inhibitors potentially useful for the treatment of cancer.
In an isomerization reaction, uridine is modified to pseudouridine, the most abundant RNA modification which presents an extra hydrogen bond donor, altering the RNA structure and providing unique chemical properties.
Trogenix Ltd. has completed its series A financing, raising £70 million ($95 million) to support progression into the clinic of its pipeline of potentially curative cancer therapies across multiple aggressive solid tumors.
Nanyang Biologics Pte. Ltd. has entered a $1.5 billion business combination agreement with RF Acquisition Corp II, a Nasdaq-listed special purpose acquisition company. Singapore-based Nanyang Biologics (NYB) is building a hybrid platform to revolutionize drug discovery by combining machine learning with natural compound libraries, and NYB claims it is developing one of the world’s largest AI-curated collections of bioactive compounds.
The U.S. FDA has approved the priority sNDA for a new first-line maintenance therapy in extensive-stage small-cell lung cancer from Jazz Pharmaceuticals plc. Zepzelca (lurbinectedin) can now be combined with Tecentriq (atezolizumab, Roche AG) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Roche) as a maintenance therapy for adults who haven’t progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.
Cogent Biosciences Inc. has disclosed prodrugs and their active metabolites acting as GTPase KRAS and their mutant inhibitors reported to be useful for the treatment of cancer.
Cartography Biosciences Inc. has closed a $67 million series B financing to support its pipeline of T-cell engaging bispecific and multispecific antibody therapeutics that target novel and highly specific tumor antigens.
At the recent American Association for Cancer Research (AACR) Special Conference on Advances in Pancreatic Cancer Research, researchers from Cellectar Biosciences Inc. presented preclinical data on [225Ac]CLR-121225 (CLR-225), a novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma.
RSS
